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Abstract 
 
Background and Purpose: Histone hypoacetylation is associated with Parkinson’s disease, 
due possibly to an imbalance between the activities of enzymes responsible for histone 
(de)acetylation; correction of which may be neuroprotective/neurorestorative. This 
hypothesis was tested using the anti-epileptic drug sodium valproate, a known histone 
deacetylase inhibitor, utilising a delayed-start study design in the lactacystin rat model of 
Parkinson’s disease. 
Experimental Approach: 10µg of the irreversible proteasome inhibitor lactacystin was 
stereotaxically injected into the left substantia nigra of Sprague-Dawley rats which 
subsequently received valproate for 28 days starting 7 days after lactacystin lesioning. 
Animals were assessed by a combined phenotyping approach, of motor behavioural testing, 
clinically comparable longitudinal structural MRI, and post-mortem assessment of the 
integrity of the rat brain nigrostriatal system to track changes in this model of Parkinson’s 
disease and quantify neuroprotection/restoration. Subsequent cellular and molecular analyses 
were performed to elucidate the mechanisms underlying valproate’s effects.  
Key Results: Despite producing a distinct pattern of structural re-modelling both in the 
healthy and lactacystin lesioned brain, delayed start valproate administration induced dose-
dependent neuroprotection/restoration against lactacystin neurotoxicity, characterised by 
motor deficit alleviation, attenuation of morphological brain changes detected using MRI, 
and protection and restoration of dopaminergic neurons in the substantia nigra. Moreover 
molecular analyses revealed that valproate alleviated histone hypoacetylation induced by 
lactacystin and induced up-regulation of brain neurotrophic/neuroprotective factors. 
Conclusions and Implications: These results suggest that histone acetylation and up-
regulation of neurotrophic and neuroprotective factors associated with valproate treatment 
culminate in a neuroprotective and neurorestorative phenotype in this validated animal model 
of Parkinson’s disease. Given the structural re-modelling in the brain induced by valproate 
these results do not suggest that valproate is a viable candidate for the disease but provide 
proof-of-principle that histone deacetylase inhibitors could hold therapeutic potential as 
disease modifying agents in Parkinson’s disease. 
 
Abbreviations 
αSyn  α-synuclein 
6-OHDA 6-hydroxydopamine  
AcH3-Lys9 histone protein H3 acetylated on lysine 9 
BDNF  brain derived neurotrophic factor 
GDNF  glial derived neurotrophic factor 
HATs  histone acetyltransferases 
HDACIs histone deacetylase inhibitors 
HDACs histone deacetylases 
HSP70  heat shock protein 70 
i.p.  intraperitoneal 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MR  magnetic resonance 
PD  Parkinson’s disease 
qRT-PCR quantitative real time polymerase chain reaction 
SNpc  substantia nigra pars compacta 
TBM  tensor based morphometry 
TH  tyrosine hydroxylase 
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Introduction 
Parkinson’s disease (PD) is the most prevalent movement disorder, with cardinal symptoms 
of rigidity, tremor and bradykinesia, primarily resulting from degeneration of the 
dopaminergic nigrostriatal pathway (Jenner et al., 2006). The pathological hallmark of the 
degenerating neurons in PD are intracytoplasmic protein inclusions known as Lewy bodies 
and Lewy neurites, composed predominantly of a synaptic protein called α-synuclein (αSyn), 
which are thought to be at least partly responsible for the dopaminergic neuronal cell death 
observed (Dexter et al., 2013; Spillantini et al., 1997).  
In recent years epigenetic mechanisms such as DNA methylation and histone 
remodelling have become implicated in PD pathogenesis (Ammal Kaidery et al., 2013). 
Increased expression or the presence of mutated forms of αSyn sequesters DNA 
methyltransferase 1 (DNMT1) to the cytoplasm in PD and the promoter region of the αSyn 
gene, SNCA, is hypomethylated in both transgenic mice and in sporadic PD (Desplats et al., 
2011). Similarly it has been observed that nuclear αSyn ‘masks’ histone proteins preventing 
their acetylation, resulting in histone hypoacetylation and subsequent apoptosis (Kontopoulos 
et al., 2006). In the healthy brain a carefully controlled balance exists between the activities 
of the two enzymes that control histone acetylation status: histone acetyltransferases (HATs) 
and histone deacetylases (HDACs). HATs facilitate the acetylation of histone N-terminal tail 
lysine residues, causing relaxation of chromatin structure and transcription factor access to 
DNA. Equally, HDACs reverse this process by removing acetyl groups from histone N-
terminal tail lysine residues causing condensation of chromatin structure and transcriptional 
repression. We and others postulate that this deregulation of the balance of histone 
acetylation and deacetylation could be rectified with the use of HDAC inhibitors (HDACIs), 
reducing the neurodegeneration observed as a result of HAT/HDAC misbalance (Chuang et 
al., 2009; Dietz et al., 2010; Hahnen et al., 2008; Harrison et al., 2013; Kazantsev et al., 
2008). 
Sodium valproate (2-propylpentanoic acid), first marketed over 45 years ago for the 
treatment of epilepsy (Löscher, 2002), is now a commonly prescribed mood stabiliser and 
anti-convulsant used to control generalised and partial seizures (Perucca, 2002). Subsequently, 
valproate was discovered to relieve HDAC-dependent transcriptional repression and cause 
histone hyperacetylation both in vitro and in vivo (Gottlicher et al., 2001; Phiel et al., 2001) 
by acting as a pan-inhibitor of HDAC classes I and IIa: inhibiting HDAC 1, 2, 3, 4, 5, 7 and 8 
with varying potencies (Gurvich et al., 2004). This property of valproate has been shown to 
reduce neuroinflammation leading to neuroprotection in cell culture models of neuroimmune 
cell activation and dopaminergic cell death (Chen et al., 2006; Kidd et al., 2010; Monti et al., 
2007; Monti et al., 2009; Peng et al., 2005; Wu et al., 2008). Furthermore, pre-clinical in vivo 
studies highlight the neuroprotective potential of valproate in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model (Kidd et al., 2011), and the rotenone (Monti et al., 
2010) and 6-hydroxydopamine (6-OHDA) (Monti et al., 2012) rat models of PD when given 
as a pre-treatment. Given its longevity of clinical use, these data suggest valproate is a 
candidate drug for clinical repositioning in the treatment of PD. Critically however, in prior 
pre-clinical neuroprotection studies, valproate was administered as a pre-treatment prior to 
administering the neurotoxin responsible for modelling Parkinsonian nigral degeneration. 
These studies were also in animal models which induce cell death through mechanisms other 
than altered protein deposition, the neuropathological hallmark of PD.  Hence, this design, 
whilst effective for proof-of-concept studies lacks any clinical translatability or relevance. 
Likewise the molecular mechanism linking inhibition of HDACs by valproate leading to 
neuroprotection remains unclear. Current evidence from pre-clinical studies is therefore 
insufficient to facilitate translation of these basic findings to the clinic.  
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In this study, for the first time we have addressed these issues by investigating the 
neuroprotective effects of delayed-start valproate treatment, initiated one week after lesioning 
the rat nigrostriatal system, using the proteasome inhibitor, lactacystin. Importantly, this 
model recapitulates the formation of neurotoxic αSyn protein inclusions, which are known to 
affect epigenetic mechanisms, within the substantia nigra to induce dopaminergic cell death 
(Pienaar et al., 2015; Vernon et al., 2010a; Vernon et al., 2011). Similarly this model is 
associated with a specific reproducible pattern of neuroanatomical changes in the brain 
overlapping that of late stage PD (Duncan et al., 2013; Vernon et al., 2010b).  For the first 
time we also use a combined phenotyping approach, combining motor behavioural testing, 
clinically comparable longitudinal structural MRI and post-mortem assessment of the 
integrity of the rat brain nigrostriatal system to track changes in this model of PD and detect 
neuroprotection. Subsequent cellular and molecular analyses were also performed to 
elucidate the mechanisms underlying valproate’s neuroprotective effects: including 
quantification of histone acetylation and expression levels of a number of different 
neurotrophic factors, apoptotic regulators and genes of interest to PD, previously shown to 
change upon treatment with HDACIs (Monti et al., 2009). 
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Materials and Methods 
Experimental Animals 
All animal procedures were carried out in accordance with the Home Office Animals 
(Scientific Procedures) Act, UK, 1986, and were previously approved by the Imperial 
College Animal Welfare and Ethical Review Board. Presentation of data complies with the 
ARRIVE guidelines (Kilkenny et al., 2010). Male Sprague-Dawley rats (250±10g, Charles 
River, UK) were housed in groups of two or three at 21±1°C on a 12 hour light dark cycle 
with the relative humidity maintained at 55±10%. Standard rat chow and drinking water were 
available ad libitum throughout the duration of the study, and were supplemented with 
standard rat wet diet for seven days post-surgery.  
 
Animal Treatment Groups 
Five animal treatment groups (Fig. 1) underwent serial evaluation of brain structure by MRI 
and motor behavioural testing. The baseline assessment was prior to lactacystin-lesioning of 
the substantia nigra pars compacta (SNpc) with follow up assessments at 1, 3 and 5 weeks 
post-surgery. Animals were injected daily for 28 days with either saline or valproate 
(200mg/kg or 400mg/kg i.p.) initiated 7 days post-surgery. After the final in vivo assessments, 
animals were sacrificed and brain tissue harvested for subsequent analysis. An additional 
group of animals was also stereotaxically lesioned with lactacystin however sacrificed and 
brain tissue harvested for subsequent analysis, 7 days post-surgery.  
 
Stereotaxic Lesioning of the SNpc with Lactacystin 
The left SNpc was stereotaxically lesioned using the irreversible proteasome inhibitor, 
lactacystin (BML-PI104, Enzo Life Sciences, Exeter, UK), as previously published (Vernon 
et al., 2010a). Briefly, isoflurane (05260-05, IsoFlo®, Abbott Laboratories, Maidenhead, UK) 
anaesthetised animals were then positioned in a stereotaxic frame (Kopf Instruments, Tujunga, 
USA) in the horizontal skull position with the incisor bar positioned 3.3mm below the 
interaural line. Intramuscular administration of buprenorphine (QN02AE01, Alstoe Animal 
Health, York, UK) provided analgesia whilst bupivacaine (PL-20910/0008, Taro 
Pharmaceuticals, NY, USA) was utilised to produce local anaesthesia in the scalp prior to 
making a midline incision to expose  the skull where bregma was identified (Paxinos et al., 
2009). A small burr hole was made in the skull above the SNpc and 10µg of lactacystin 
(2.5µg/µl in sterile (0.9%) saline, 4µl in total) was stereotaxically administered via a 
Hamilton syringe to the SNpc: anterio-posterior, -5.2mm, medio-lateral, +2.5mm and ventral 
to dura, -7.6mm (Paxinos et al., 2009). The lactacystin was injected at a rate of 1µl/min, the 
needle was left in situ for 3mins before being retracted. Post-surgery fluid replacement 
(Glucosaline, 5ml of 0.18% NaCl, 4% Glucose, given i.p. prior to surgery) was administered 
and animals were left to recover in a heated recovery chamber.  
 
Behavioural Testing 
Vertical Cylinder Test  
To assess asymmetry in forelimb motor function the vertical cylinder test was employed 
similar to that previously published (Schallert et al., 2000). Briefly, animals were placed into 
a Perspex cylinder (200mm diameter by 300mm height) and rearing behaviour was recorded 
with a video camera for either ten complete rears or 3mins. Forelimb movements were 
examined using frame by frame analysis of video recordings. The percentage of contralateral 
forelimb use was calculated as: 
 
N =    (no. of uses of contralateral forelimb + ½ no. of uses of both forelimbs simultaneously) x100) 
           (no. of uses of ipsilateral forelimb + contralateral forelimb + both forelimbs simultaneously) 
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Amphetamine Induced Rotation Test 
Rotational asymmetry was assessed using the amphetamine induced rotation test similar to 
that previously published (Ungerstedt et al., 1970). Briefly, animals were administered 
5mg/kg amphetamine (i.p., D-amphetamine sulphate (A0922, Sigma, Poole, UK) in sterile 
saline at 5mg and placed in a clear circular test arena of dimensions 400mm diameter by 
360mm height (Circling Bowl, Harvard Apparatus, MA, USA) for 30mins to acclimatise. 
After this time behaviour was recorded for 30mins and the numbers of contraversive and 
ipsiversive rotations were counted in bins of 5 minutes. The net number of ipsiversive 
rotations per 5 minute bin was calculated as: 
 
N = (no. of ipsiversive rotations) – (no. of contraversive rotations) 
 
Magnetic Resonance Imaging  
T2-weighted (T2W) magnetic resonance (MR) images were acquired similar to that 
previously described (Vernon et al., 2010a; Vernon et al., 2011) using a 4.7 Tesla 
DirectDrive horizontal small bore MRI scanner (Varian, Palo Alto, CA, USA) and a separate 
72mm quadrature birdcage head RF coil (M2M Imaging, OH, USA) linked to a LINUS-
based control console running VnmrJ acquisition software (v2.3, Varian). Briefly, animals 
were anaesthetised by inhalation of isoflurane vaporised into O2 in an anaesthetic chamber. 
The animal was then positioned into an MRI compatible polytetrafluroethylane (PTFE) 
stereotaxic head holder and bed (M2M Imaging, OH, USA) and maintained under anaesthesia 
using isoflurane. Depth of anaesthesia was monitored using a respiratory balloon (SA 
Instruments, Stoney Brook, NY, USA) placed under the animal’s chest and body temperature 
was monitored and maintained using a rectal probe and heated fan (SA Instruments), 
respectively. T2W images were acquired using a multi-echo, multi-slice spin-echo pulse 
sequence (MEMS), with the following scan parameters: FOV=35mm×35mm; 
matrix=192×192; TR=5155.2ms; TE=10, 20, 30, 40, 50, 60, 70, 80, 90, 100ms; 4 averages, 
scan duration 1hr 5mins 59secs. Fifty contiguous 500µm thick coronal slices with an in plane 
resolution of 256×256µm were acquired such that the entire brain of each animal was covered. 
Once scanning was completed, animals were removed from the magnet bore to a separate 
holding room and placed in a heated recovery chamber. Following full recovery from 
anaesthesia, animals were then returned to their home cages. 
 
MR Image Analysis 
Post-acquisition, images corresponding to the ten TE times used were summed using the “Z 
Project” function in ImageJ (v1.4, National Institutes of Health, Bethesda, MD, USA) to give 
the fifty T2W images representing fifty contiguous 500µm thick coronal slices of the rat brain. 
For regional volumetric analysis of MR images, structures were delineated manually 
using ImageJ software by a single rater blinded to animal treatment. Six brain regions (whole 
brain, lateral ventricles, corpus striatum, hippocampus, midbrain and cerebellum) were 
delineated based on anatomical landmarks previously published (Vernon et al., 2010a; 
Vernon et al., 2011) and with reference to the rat brain stereotaxic map (Paxinos et al., 2009) 
(Supplementary Fig. 1). Volumes were then calculated by multiplying the sum of the areas 
for a given structure on all slices by the slice thickness (500µm). Brain volumes were then 
expressed as percentage change from baseline.  
To perform an unbiased whole-brain analysis of apparent volumetric differences 
between groups, an automated image-processing pipeline for Tensor Based Morphometry 
(TBM) was used (Crum et al., 2013a). Briefly, a single, well-positioned good-quality control 
animal (surgically naïve, saline treated) scan was chosen as an initial reference for rigid (6 
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degrees of freedom) and rigid + scaling (9 degrees of freedom) registration using a robust 
population approach (Crum et al., 2013b). Then, a template image was constructed as the 
mean of the registered control group (surgically naïve, saline treated) scans and used as the 
reference in subsequent processing. High-dimensional non-rigid registration was applied to 
each scan to warp it onto the control template, and thereby obtain maps of apparent local 
volume difference for each scan, encoded as the Jacobian determinant at each voxel (Crum et 
al., 2013a). Non-parametric t-tests at each voxel were used to detect differences in the 
Jacobian determinants between each study group and the control group and thereby infer 
differences in volume across groups (Bullmore et al., 1999). Significance values were 
corrected for multiple comparisons using the False Discovery Rate with q=0.05 (Genovese et 
al., 2002). 
 
Tissue Collection and Preparation 
At the end of the study period, animals were sacrificed, decapitated and the brain removed 
from the skull. Using a rodent brain matrix, each brain was cut coronally at the level of the 
infundibular stem to produce forebrain and hindbrain blocks. Frontal brain tissue was 
dissected out, snap frozen on dry ice and stored at -80°C for protein and mRNA extraction. 
The hindbrain was fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) (pH 7.4) 
for 72hrs before being cryoprotected in 30% sucrose in PBS until the tissue was observed to 
have sunk. Blocks were then snap frozen in isopentane pre-chilled on dry ice and stored at -
80°C for subsequent sectioning.  
 
Immunohistochemistry 
30µm thick coronal sections were collected throughout the extent of the SNpc onto 
SuperFrost® Plus slides (HECH2409/1, VWR international, Lutterworth, UK) using a 
cryostat (Bright Instruments, Huntingdon, UK). Slides were then stored at -80°C until 
analysis. Immunohistochemistry for tyrosine hydroxide (TH), the rate limiting enzyme in 
monoamine synthesis was utilised as the cellular marker for dopaminergic neurons in the 
SNpc, and cresyl violet was used as a counterstain for the Nissl body of all neurons. For this 
the Avidin-Biotin Complex (ABC)/peroxidase method of immunohistochemistry with a 
cresyl violet counterstain was performed similar to that previously published by our group 
(Pienaar et al., 2015). Briefly, endogenous peroxidase activity was blocked by incubation in 
0.3% H2O2 in methanol for 45mins before sections were rehydrated in a descending series of 
alcohol washes followed by PBS containing 0.1% TritonX-100 (PBS-T). Non-specific 
binding was blocked by incubation with 20% normal goat serum in PBS-T for 1hr at room 
temperature before incubating with the primary antibody (Rabbit Polyclonal Anti-Tyrosine 
Hydroxylase, AB152, Millipore, MA, USA) at 1:1000 in PBS-T for 24hrs at room 
temperature. Sections were then washed in PBS-T and incubated in the secondary antibody 
(Biotinylated Goat Anti-Rabbit Secondary Antibody, BA-1000, VectorLabs, Peterborough, 
UK) at 1:200 in PBS-T for 1hr at room temperature. Sections were then washed again and 
incubated in Avidin-Biotin Complex (Vectastain Elite ABC Kit, PK-6200, VectorLabs) for a 
further 1hr at room temperature before being washed thoroughly in Tris-Buffered Saline 
(TBS) (pH 8.4), and staining visualised with 3, 3'-diaminobenzidine (DAB). Sections were 
then washed in H2O before being counterstained using cresyl violiet (0.1% in dH2O) for 
2mins and mounted.  
 
Stereological Cell Quantification 
Stereological quantification of the number of TH positive (TH+) and Nissl positive (Nissl+) 
cells were made in the entire SNpc. For this, a computer based stereology software system 
(ImagePro, MediaCybernetics, PA, USA) attached to a Nikon Eclipse E8—microscope 
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(Nikon Instruments, Surrey, UK) and JVC (London, UK) 3CCD camera was used. The 
optical fractionator method of stereology was used as previously published (West et al., 
1991). Briefly, for each section the SNpc was delineated manually with relation to previously 
published boundaries (Carman et al., 1991), to create an area of interest (AOI). The software 
system then created counting frames (140 x 160µm) which fell within the AOI using the 
uniform random sampling method. The total area of the counting frames relative to the area 
of the AOI gives the area sampling fraction (asf). The height of the optical dissector, which 
was measured by taking an average of 3 random points across the section using a Heidenhain 
microcator (Hedenhain, Traunreut, Germany), relative to the section thickness gives the 
height sampling fraction (hsf). The section sampling fraction (ssf) was 1/6 as every 6th 
section throughout the SNpc was analysed. To avoid edge effects, when counting TH+ and 
Nissl+ cells within the counting frames, “acceptance” and “forbidden” lines were used. Total 
cell estimates were calculated as follows, where n equal the number of positive cells counted:  
 
N = n (1/ssf) (1/asf) (1/hsf) 
 
Protein and mRNA Extraction and Quantification 
30mg of frontal brain tissue was homogenised in QIAzol® Lysis Reagent (79306, Qiagen, 
Crawley, UK) using a tissue homogeniser (Ultra-Turrax T18, IKA, Staufen, Germany). 
mRNA and protein was extracted from homogenised brain tissue using the RNeasy® Plus 
Universal Mini Kit (73404, Qiagen) as per the manufacturer’s instructions. Isolated RNA was 
quantified spectrophotometrically using a NanoDrop ND-1000 spectrophotometer (Thermo 
Fischer Scientific, Waltham, MA, USA) and RNA purity verified by an average A260/280 ratio 
of 1.99 (range 1.97-2.01). The quantity of isolated protein was determined using the 96-well 
variant of the Bradford Assay (B6916, Sigma): colour change determined using a 96-well 
plate reader (VersaMax Microplate Reader, Molecular Devices, CA, USA) at A595. mRNA 
and protein were stored at -80°C and -20°C respectively until further analysis.  
 
Western Blot Analysis 
Laemmli sample buffer (S3401, Sigma) was added to 10µg of extracted protein sample and 
denatured by incubating at 95°C for 15mins. Samples were loaded onto a 1mm thick hand-
cast 15% Tris-Glycine gel and proteins were separated by electrophoresis (65mA for 40mins). 
Proteins were transferred onto methanol soaked PVDF membrane with a pore size of 0.45µm 
using semi-dry transfer (20V for 45mins). Membranes were then equilibrated in TBS 
containing 0.2% Tween-20 (TBS-T), before being blocked in 5% non-fat milk in TBS-T for 
1hr at room temperature. Membrane was washed in TBS-T again before being incubated in 
primary antibodies against histone protein H3 acetylated on lysine 9 (rabbit anti-AcH3-Lys9, 
H9286, Sigma, 1:10,000) and mouse anti-β-actin antibody (1:20,000, Ab6276, Abcam, 
Cambridge, UK) for 1hr at RT. Membranes were then washed again and incubated in 
horseradish peroxidase (HRP)-conjugated secondary antibodies (either Goat anti-Rabbit 
[1:10,000] and Horse anti-Mouse [1:10,000] for AcH3-Lys9 or β-actin respectively, both 
Vector Laboratories) for 1hr at RT. Membranes were washed again in TBS-T and developed 
using chemiluminescence (170-5060, Clarity Western ECL Substrate, Bio-Rad, Hemel 
Hempstead UK). Bands were quantified using densitometry analysis software (ImageJ, v1.4).  
 
Quantitative Real Time Polymerase Chain Reaction 
For cDNA synthesis, 500ng of total RNA from each sample was reverse transcribed 
according to the manufacturer's instructions using the QuantiTect® reverse transcription kit 
(205310, Qiagen) with integrated removal of genomic DNA contamination. The reactions 
were stored at -20°C until further use. Real-time reverse transcriptase quantitative 
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polymerase chain reaction (RT-qPCR) experiments were performed using a Mx3000P™ real-
time PCR system with MxPro software (v4.10, Stratagene, La Jolla, CA, USA) and the 
Brilliant® II QPCR master mix with low ROX (600806, Agilent technologies UK Ltd, 
Edinburgh, UK). For each gene of interest in each sample, 20µl reactions were set up in 
triplicate, and run in duplex with a novel reference gene (XPNPEP1 [X-prolyl 
aminopeptidase (aminopeptidase P) 1] (Durrenberger et al., 2012)), with each reaction 
containing 10µl of 2× Brilliant® II QPCR master mix, 7 µl of RNase-free water, 1 µl 
template cDNA, 2µl (1µl gene of interest + 1µl reference gene) of 10× PrimeTime™ qPCR 
assays (Integrated DNA technology, Coralville, IA, USA, Supplementary Table 1). Reactions 
were carried out with the following cycling protocol: 95°C for 10 min, then 60 cycles with a 
3-step program (95°C for 30s, 55°C for 30s and 72°C for 30s). Fluorescence data collection 
was performed during the annealing step. A negative control containing no cDNA template 
was also run in each plate. Similarly an inter-plate calibrator, created by pooling control 
cDNA samples, was also run in each plate. Relative gene expression was determined using 
the 2−∆∆CT method  normalising to the expression of the novel reference gene (Durrenberger 
et al., 2012) and the appropriate control group. 
 
Statistical Analysis 
All data is presented as mean ± standard error of mean (SEM). Two-way (repeated measures) 
analysis of variance (ANOVA) with Bonferroni post-tests were used for analysis of vertical 
cylinder test, amphetamine induced rotation test and MRI manual segmentation analysis 
datasets. An unpaired t-test was used to compare the baseline and week 1 forelimb use of 
lactacystin-lesioned animals in vertical cylinder test data. Paired t-tests were used to compare 
stereological cell counts in the ipsilateral and contralateral hemispheres of animal brains. A 
one-way ANOVA with Bonferroni post-tests were used to compare cell loss percentages 
calculated from stereological cell counts. A two-way ANOVA with Bonferroni post-tests 
were used to compare qRT-PCR data. A one-way ANOVA with Bonferroni post-tests were 
used to compare Western blot data. All statistical tests were performed using GraphPad Prism 
(v5.0 for Windows, GraphPad Software, San Diego, CA, USA). 
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Results 
Valproate Attenuates Behavioural Motor Deficits Caused by Lactacystin  
The vertical cylinder test and amphetamine induced rotations were utilised to assess for 
motor asymmetry in the animals’ movement due to unilateral injection of lactacystin into the 
SNpc. 
Vertical Cylinder Test 
At baseline there was equal use of both the left and right forelimbs in all animals (Fig. 2A, 
51.69±0.89% contralateral forelimb use). However, one week after surgery there was a 
significant reduction in the contralateral forelimb use of lactacystin-lesioned animals 
compared with non-lesioned animals (week 1, mean forelimb use of lactacystin-lesioned 
animals, 37.99±1.53%, vs. mean forelimb use of non-lesioned animals, 53.69±1.38%, p<0.05 
in all comparisons). Contralateral forelimb use of saline treated animals continued to decline 
with time (week 1, 39.59±4.11%; week 3, 36.01±3.37%; week 5, 35.50±4.08%, p<0.01 
compared with control animals at each time point). However, the continued decline in motor 
deficits due to lactacystin toxicity from week 1 was halted in animals treated with the lower 
dose of valproate (200mg/kg) (week 5, valproate, 44.39±6.94% vs. saline treated animals, 
35.50±4.08%). Whereas in animals treated with the highest dose of valproate (400mg/kg) the 
continued decline in motor deficits due to lactacystin toxicity from week 1 was totally 
reversed with the animals failing to show any deficit after 28 days of treatment (week 5, 
valproate, 52.63±2.66% vs. saline treated animals, 35.50±4.08%, p<0.01). 
Amphetamine Induced Rotations 
Ipsilateral rotations following an amphetamine challenge were observed at one week in all 
lactacystin-lesioned animals (Fig. 2B, 20.44±3.35 net ipsiversive rotations per 5 minutes). 
Saline treated lactacystin-lesioned animals performed increasing numbers of rotations over 
the further two time points examined (area under curve produced by plotting number of 
rotations vs. time, Fig. 2C, week 1, 612.01±121.59; week 3, 1039.33±247.75; week 5, 
1641±477.50). However animals treated with the lowest dose of valproate performed fewer 
rotations than saline treated animals after 28 days of valproate treatment, whereas animals 
treated with the highest dose of valproate (400mg/kg) perform fewer rotations than the saline 
treated group after both 14 and 28 days valproate treatment (week 5, valproate, 
585.83±123.47 vs. saline treated animals, 1641±477.50, p<0.05).  
 
MRI Reveals Dose-dependent Attenuation of Lactacystin Induced Volumetric Changes 
by Valproate 
In vivo rat brain MR images were acquired longitudinally to follow the neuropathological 
progression of the lactacystin PD model as previously described (Vernon et al., 2010a; 
Vernon et al., 2011). A combination of manual segmentation analysis and automated, 
unbiased TBM were used to quantify neuropathological changes observed as a result of 
lactacystin-lesioning and determine the effects of valproate treatment upon this progression. 
Manual Segmentation Analysis 
No significant difference was observed in baseline brain volume between groups (data not 
shown) however to account for individual variations in brain size, data is presented as 
percentage change from baseline. In line with rat growth and consistent with MRI finding in 
rats of comparable age to those used in this study, there was a steady increase in whole brain 
volume in surgically naïve saline treated animals over the 5 week study (Fig. 3A, week 1, 
2.09±0.86%; week 3, 4.64±1.33%; week 5, 6.60±1.29% increase from baseline). Lactacystin-
lesioned animals treated with saline and lesioned animals treated with the lower dose of 
valproate however both exhibit a greater increase in brain volume compared to control 
animals (9.07±2.44% and 9.33±0.69% increase from baseline at week 5 respectively vs. 
6.60±1.29% increase in control animals). Whereas animal groups treated with valproate at its 
Harrison et al.                            Valproate Neurorestoration in Parkinsonian Rats 
11 
 
higher dose, both lactacystin-lesioned and surgically naïve, exhibit a discernible shallower 
increase in whole brain volume over the 5 weeks of treatment (3.76±1.19% and 3.07±1.34% 
increase from baseline at week 5 respectively vs. 6.60±1.29% increase in control animals).  
In surgically naïve animals, the volume of the lateral ventricles increases comparably 
in both hemispheres over the 5 week study (Fig. 3B). However, lactacystin-lesioned animals 
subsequently treated with saline, exhibit a greater increase in ventricular volume, a change 
which was more pronounced in the lesioned hemisphere. In contrast, lactacystin-lesioned 
animals treated with valproate (both 200mg/kg and 400mg/kg) do not exhibit these increases 
in ventricular volume over time (left ventricle at week 5, 200mg/kg and 400mg/kg valproate 
treated animals, 40.81±28.20% and 60.05±14.17% increase from baseline respectively 
compared with saline treated animals, 192.93±61.54% increase from baseline, both p<0.05). 
One week after lesioning surgery, prior to starting vehicle/drug treatment, the 
ipsilateral midbrain volume of all lactacystin-lesioned animal groups was significantly lower 
than the volume of both surgically naïve groups (Fig. 3C, lactacystin-lesioned saline, 
200mg/kg and 400mg/kg valproate treated animals, 7.07±3.05%, 4.51±2.42% and 4.74±0.83% 
decrease from baseline respectively vs. 10.88±4.73% and 13.80±3.08% increase in non-
lesioned saline treated and valproate treated groups respectively, p<0.05 in all comparisons). 
The ipsilateral midbrain volume in lactacystin-lesioned saline and low dose (200mg/kg) 
valproate treated animals continued to decline over the further two time points examined, 
remaining significantly different from the volume change in surgically naïve groups at both 
week 3 and week 5 (p<0.001 in all comparisons). In contrast, lactacystin-lesioned animals 
treated with the higher dose (400mg/kg) of valproate display a reversal of the decrease in 
ipsilateral midbrain volume seen at week 1 in the following two time points: reaching a 
significant difference from saline and low dose (200mg/kg) treated animals at week 5 
(400mg/kg valproate treated animals, 3.70±2.36% increase from baseline vs. saline and 
200mg/kg valproate treated animals, 16.77±5.94% and 15.90±2.36% decrease from baseline 
respectively, p<0.01 in both comparisons). Identical albeit more subtle changes are similarly 
observed contralateral hemisphere of the midbrain. 
No significant differences are observed in corpus striatum volume in either the 
ipsilateral or contralateral hemispheres. However a number of trends in the ipsilateral 
hemisphere exist subtly mimicking those changes observed in the midbrain (Supplementary 
Fig. 2). Similarly no discernible changes in volume of the either ipsilateral or contralateral 
hippocampus, or the cerebellum were observed (Supplementary Fig. 2). 
Tensor Based Morphometry Analysis 
To confirm and extend our manual segmentation observations, we applied TBM analysis to 
MR images acquired from all groups 5 weeks post-surgery (Fig. 4). After correcting for 
global differences in brain volume (9dof registration) to search for relative differences in 
brain volume, several distinct anatomical patterns were observed across treatment groups (all 
data shown are corrected for multiple-comparison over voxels using the False Discovery Rate 
with q<0.05).  
Surgically naïve animals treated with valproate, showed bilateral clusters of 
contracted voxels in the globus pallidus, internal capsule, third ventricle, ventromedial 
thalamic nuclei, perirhinal cortex, amygdala and brainstem. Conversely, clusters of expanded 
voxels were detected in the hippocampus (dorsal and ventral regions), dorsal entorhinal 
cortex, external capsule and the 3rd and 4th cerebellar lobules.   
In lactacystin-lesioned animals treated with saline, we observed widespread 
significant contraction of cortical voxels in the ipsilateral (lesioned) hemisphere of the brain. 
These included the cingulate, motor, somatosensory and parietal cortical sub-fields. Sub-
cortically, widespread clusters of contracted voxels were observed in the ipsilateral striatum, 
globus pallidus, thalamus, ventral midbrain and brainstem nuclei. Some of these clusters 
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extended across the midline into the contralateral (non-lesioned) hemisphere. No significantly 
contracted voxels were observed in the hippocampus. Clusters of significantly expanded 
voxels were also observed in the ipsilateral hemisphere. Primarily this reflected an increase in 
cerebrospinal fluid signal accompanying deformation of the ventral midbrain. Significantly 
expanded voxels were however also seen in the cerebellar white matter and dorsolateral 
entorhinal cortex.  
In lactacystin-lesioned animals treated with low (200mg/kg) and high doses 
(400mg/kg) of valproate a more complex pattern of anatomical changes were detected. 
Valproate treatment dose-dependently reversed cortical atrophy in the cingulate, motor, 
sensorimotor and parietal cortices in the ipsilateral (lesioned) hemisphere.  Sub-cortically, 
valproate treatment also dose-dependently reversed atrophy of the ventromedial thalamus, 
ventral midbrain and expansion of CSF space. These effects were more marked at the higher 
dose tested. Drug-specific effects of valproate were however also present, which make 
interpretation of the results difficult. Indeed, low dose valproate treatment resulted in bilateral 
atrophy in the ventromedial thalamus, globus pallidus, internal capsule and third ventricle. 
These patterns are consistent with the effects of valproate in non-lesioned animals. These 
patterns were however, paradoxically not present in lesioned animals given a high dose of 
valproate. 
 
Valproate Treatment Causes Dose-dependent Protection/Restoration of Dopaminergic 
Neurons in the SNpc in Lactacystin Lesioned Animals 
Post-study, animals were culled and hind brain tissue collected for immunohistochemical 
staining and stereological quantification of dopaminergic neurons (tyrosine hydroxylase 
positive (TH+)) in the SNpc (Fig. 5 and 6). Non-lesioned animals treated with either saline or 
valproate (400mg/kg) did not show any interhemispheric loss of TH+ neurons in the SNpc. 
Animals lesioned with lactacystin and culled 7 days post-surgery, the time point when 
valproate administration was initiated, however exhibit a marked interhemispheric loss of 
TH+ neurons due to the intranigral injection of lactacystin (left SNpc, 7817±1734 vs. right 
SNpc, 14027±538 TH+ cells, -45.17±10.96% difference, p<0.05). The loss of TH+ neurons 
continued to increase with time, rising to -64.24±11.34% in the lactacystin-lesioned animals 
treated with saline for 28 days, demonstrating further neurodegeneration after week 1 (left 
SNpc, 4257±1364 vs. right SNpc, 12328±580 TH+ cells, % difference, -64.24±11.34, 
p<0.01). In contrast valproate administration in lactacystin-lesioned animals resulted in a 
dose-dependent neuroprotective/restorative effect. When administered at its higher dose 
(400mg/kg) for 28 days afforded near complete protection/restoration of SNpc TH+ neurons 
against the toxic effects of lactacystin (left SNpc, 9729±1347 vs. right SNpc, 11913±578 
TH+ cells, % difference -19.08±10.17%, p>0.05). Similarly, administration of the lower dose 
(200mg/kg) of valproate resulted in only a partial protection of the TH+ neurons against 
lactacystin toxicity (left SNpc, 7659±1228 vs. right SNpc, 12739±862 TH+ cells, % 
difference -40.26±9.87%, p<0.05). All changes observed in SNpc TH+ cell number were 
reproduced in the numbers of Nissl+ cell number, indicative of TH+ neuronal cell death 
rather than loss of the TH enzyme expression in dying neurons.  
 
Valproate Dose-dependently Attenuates Lactacystin Induced Reduction in Histone 
Acetylation  
Upon removal of brain tissue at the end of the study the frontal brain was snap frozen for 
subsequent quantification histone acetylation through quantification of histone protein H3 
acetylated on lysine 9 (AcH3-Lys9) using Western blot analysis (Fig. 7). Significantly less 
AcH3-Lys9 was observed in both hemispheres lactacystin-lesioned animals treated with 
saline compared with non-lesioned animals (left hemisphere, non-lesioned animals, 
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0.77±0.10 vs. lactacystin-lesioned animals, 0.02±0.03, right hemisphere, non-lesioned 
animals, 0.88±0.09 vs. lactacystin-lesioned animals, 0.18±0.06, p<0.01 in both comparisons). 
This effect was dose-dependently attenuated in both hemispheres of animals treated with 
valproate, reaching significance from saline treated animals in the ipsilateral hemisphere 
(ipsilateral hemisphere, saline treated animals, 0.02±0.03 vs. animals treated with 400mg/kg 
valproate, 0.84±0.08, p<0.05). No difference in the amount of AcH3-Lys9 in either 
hemisphere was observed in non-lesioned animals treated with valproate compared with 
control.  
 
Valproate Upregulates Expression of Neurotrophic Growth Factors and 
Neuroprotective Proteins 
In non-lesioned animals, administration of valproate induced a marked upregulation of brain 
derived neurotrophic factor (BDNF) (Fig. 8A, ipsilateral valproate treated, 2.14±0.36 times 
greater than saline treated controls, p<0.001; contralateral valproate treated, 1.94±0.36 times 
greater than saline treated controls, p<0.01). Valproate did not alter the expression of the 
other genes examined in these surgically naïve animals. However, in lactacystin-lesioned 
animals valproate significantly and dose-dependently up regulated the expression of BDNF, 
glial derived neurotrophic factor (GDNF) and the anti-apoptotic factor Bcl2, in the frontal 
brain hemisphere contralateral to the lesion. Most notably GDNF expression was greater in 
the contralateral hemisphere of valproate compared with saline treated animals (Fig. 8B, high 
dose (400mg/kg) treated animals, 5.15±1.48 times greater than saline treated controls; low 
dose (200mg/kg) treated animals 4.32±1.34 times greater than saline treated control, p<0.001 
in both comparisons). Similarly, expression of BDNF and Bcl2 was elevated in a dose-
dependent manner in the frontal brain hemisphere contralateral to the lesion, however this 
only reached significance at the higher dose of valproate (BDNF expression, 4.08±0.88 times 
greater than saline treated control, p<0.01; BCL2 expression, 3.09±0.32 times greater than 
saline treated control, p<0.05). Similar trends of an up regulation of gene expression of native 
αSyn and heat shock protein 70 (HSP70) upon treatment with valproate were observed but 
these did not reach significance.  
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Discussion 
Valproate dose-dependently afforded neuroprotection and neurorestoration of nigrostriatal 
dopaminergic neurons in the lactacystin animal model of PD, as evidenced by an attenuation 
of motor behavioural deficits, longitudinal MRI brain volume changes and quantification of 
the dopaminergic neurons within the SNpc. Molecular analyses indicate that valproate’s 
neuroprotective effects may be mediated through epigenetic changes via inhibition of histone 
deacetylation, chromatin remodelling and upregulation of neurotrophic and neuroprotective 
genes, culminating in the observed neuroprotective and neurorestorative effect.  
MR imaging studies using toxin-based models of PD have largely been focused on 
alterations in T2 water 1H relaxation time and 1H MR spectroscopy, whilst potential 
morphological changes have been overlooked. Recently however, a method of using MRI to 
non-invasively monitor the morphological progression and nigrostriatal neuropathology in 
this proteasome inhibitor rat model of PD has been established (Vernon et al., 2010a; Vernon 
et al., 2011). To the best of our knowledge, the current study is the first to use this method in 
conjunction with a candidate neuroprotective drug to longitudinally assess its efficacy in an 
animal model of PD. Manual segmentation analysis was performed to examine the temporal 
progression of morphological changes in selected brain regions. In line with previously 
published data following nigrostriatal neuropathology induced as a result of SNpc lactacystin 
(Vernon et al., 2010a; Vernon et al., 2011) we observed a marked reduction in the volume of 
the ipsilateral midbrain in the weeks following lactacystin-lesioning. Similarly we observe an 
increase in the volume of the lateral ventricles; more pronounced in the ipsilateral as opposed 
to the contralateral hemisphere. Both of these changes were dose-dependently attenuated by 
delayed start valproate treatment. Automated, unbiased TBM analysis (Crum et al., 2013b; 
Vernon et al., 2011) confirms and extends the manual segmentation data. Indeed, TBM 
highlights that chronic valproate treatment by itself induces a specific pattern of structural re-
modelling (expansion and contraction) in the healthy brain. This is interesting in light of 
recent observations for other psychotropic drugs, including Lithium, a mood stabiliser 
(Vernon et al., 2013; Vernon et al., 2012). Similarly TBM data confirms lactacystin-lesioning 
by itself is associated with a specific reproducible pattern of neuroanatomical changes in the 
brain, detectable by MRI (Vernon et al., 2011), modelling features of advanced PD, and also 
atypical forms of PD, such as Progressive Supranuclear Palsy and Multiple System Atrophy 
(Duncan et al., 2013; Vernon et al., 2010b). This both enhances the validity of the 
lactacystin-model and confirms that our analysis pipeline is robust and reproducible enough 
to detect the same patterns in data generated and acquired in different academic centres. 
These data suggest a complex pattern of drug x disease interactions drive the anatomical 
effects observed herein. On the one hand, TBM identifies a clear neuroprotective effect of 
valproate, namely prevention of brain atrophy, entirely consistent with manual segmentation 
results. On the other hand, valproate itself induces both brain atrophy and growth in 
topographically distinct brain regions, reinforcing the importance of examining drug effects 
in both normal and diseased animals. Nevertheless, our unbiased, automated approach re-
enforces our manual observations. That is, we are able to detect a dose-dependent 
neuroprotective effect of valproate on lactacystin-induced brain atrophy, which was 
associated with both cellular and functional neuroprotection and neurorestoration. The 
combination of longitudinal in vivo MRI and automated TBM, a clinically comparable 
technology, therefore has great potential for pre-clinical assessment of drugs with disease-
modifying potential in pre-clinical models of PD, and other neurological disorders, which 
may speed the translation of basic findings to the clinic. 
 The data described here importantly illustrates the neuroprotective effects of valproate 
when administered post-lesion in the lactacystin rat model of PD are consistent with previous 
studies in which valproate was administered prior to the neurotoxin in other pre-clinical PD 
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models. Monti and colleagues (2010) observed that dietary pretreatment resulted in a 
significant preservation of the SNpc TH+ dopaminergic neurons in rats sub-chronically 
administered rotenone. They also observed an attenuation of the loss of striatal dopamine and 
consistent with in vitro findings from their group (Monti et al., 2007) they observed an 
increase in native αSyn expression in the SNpc and striatum in line with a reduction in mono-
ubiquitinated αSyn and its nuclear translocation following valproate administration. αSyn is 
thought to result in histone hypoacetylation through its ‘masking’ of histone proteins 
(Kontopoulos et al., 2006). Therefore consistent with the lack of αSyn nuclear translocation, 
the group also observe an increase in histone acetylation upon valproate treatment. Monti and 
colleagues (2012) also demonstrated that dietary pretreatment with valproate resulted in 
protection of the dopaminergic neuronal terminals in the striatum as well as the dopaminergic 
cell bodies in the SNpc against striatally administered 6-OHDA. Similarly, Kidd and 
Schneider (2011) demonstrated the neuroprotective effects of valproate, at both the SNpc 
dopaminergic cell body and striatal dopamine level, when administered systemically prior to 
the administration of the mitochondrial toxin MPTP to mice. Importantly, in all of these 
studies valproate was administered prior to the toxin and hence they do not mirror the clinical 
setting in which a neuroprotective agent will currently be used: by the time the cardinal motor 
symptoms of PD become evident, 60-70% of neurons in the SNpc and ~80% of striatal 
dopamine have already been depleted (Riederer et al., 1976). Conversely, in this important 
study we have for the first time shown valproate to be both neuroprotective and 
neurorestorative when administered one week after toxin administration in a ‘delayed start 
design’, when the neurodegenerative process has been initiated and we can already observe 
clinical behavioural and MRI changes in the animal model. Stereological quantification of 
dopaminergic neurons in animals culled one week post lactacystin-lesion, i.e. the point at 
which valproate treatment was started; indicate that the vast majority of nigral degeneration 
occurs in these first seven days. Importantly however, despite the delayed start in treatment, 
less neurodegeneration of nigral dopaminergic neurons was observed after four weeks of 
valproate treatment, indicating that valproate is not only acting neuroprotectively towards 
dopaminergic nigral neurons but is also acting neurorestoratively. Appropriately, Nissl+ 
neuronal degeneration was markedly less than that of TH+ cells in animals culled prior to 
valproate treatment. It could be possible then that valproate in the current study is acting to 
rescue unhealthy and/or dying neurons that have lost TH expression in the cell body and 
therefore have reduced function, yet retain their TH+ projections, aiding their functional 
recovery, translating to performance recovery in behavioural tests such as the vertical 
cylinder test. 
Valproate has also been shown to partially protect against motor deficits in animal 
models of traumatic brain injury (Dash et al., 2010), spinal cord injury (Lee et al., 2012) and 
stroke (Kim et al., 2007) yet to our knowledge the present study is the first to examine the 
ability of valproate to relieve motor symptoms in an animal model of PD. We demonstrate 
that delayed valproate treatment dose-dependently reverses lactacystin induced reduction in 
the use of the forelimb contralateral to the lesion, and also attenuates the number of rotations 
performed upon amphetamine challenge. Interestingly, using a battery of behavioural tests, 
Castro and colleagues (Castro et al., 2012) also demonstrated that valproate pre-treatment 
prevented the development of early non-motor symptoms of PD e.g. cognitive and emotional 
deficits, in animals nasally administered MPTP (Prediger et al., 2011). Authors  demonstrated 
that this was accompanied by a significant preservation of olfactory bulb and striatal 
dopamine content in MPTP treated animals (Castro et al., 2012). This suggests that valproate 
is also neuroprotective to other neuronal systems which is particularly important since the 
neurodegenerative process in PD is not merely confined to the dopaminergic nigrostriatal 
system (Braak et al., 2003). Our MRI findings are consistent with this: lactacystin induced 
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atrophy in numerous extra-nigral brain regions such as the cingulate, motor, sensorimotor and 
parietal cortices are ameliorated by valproate.  
The misbalance between HATs and HDACs which are thought to lead to histone 
hypoacetylation in neurodegeneration was first noted by Rouaux and colleagues (2003). 
Since then, histone hypoacetylation has become heavily implicated in neurodegenerative 
diseases such as PD: it being demonstrated that αSyn accumulation actively promotes histone 
hypoacetylation both in vitro in SH-SY5Y cells and in vivo in drosophila, both 
overexpressing αSyn (Kontopoulos et al., 2006). Lactacystin dopaminergic neurotoxicity is 
associated with the aggregation of αSyn to form inclusion bodies in the SNpc, a finding 
which has been extensively verified since (McNaught et al., 2002; Niu et al., 2009; Vernon et 
al., 2011; Zhu et al., 2007). αSyn is thought to result in histone hypoacetylation through its 
‘masking’ of histone proteins (Kontopoulos et al., 2006). Therefore in line with these 
previous observations of the effect of αSyn on histone acetylation, in the current study we 
observed a reduction in histone protein H3 acetylated on lysine 9, in the brains of lactacystin-
lesioned animals, used as a surrogate marker for histone deacetylation in the brains of these 
animals. Importantly, valproate treatment was observed to dose-dependently attenuate this 
histone hypoacetylation, in parallel with the cellular neuroprotective and restorative effect of 
the drug shown through stereological cell quantification of SNpc dopaminergic neurons. 
Valproate is a somewhat promiscuous drug: affecting glutamatergic and GABAergic 
transmission in the brain, and modulating ionic channels such as the voltage gated Na+ and T-
type Ca2+ channels. However, the dose-dependent attenuation of histone hypoacetylation 
induced by valproate in line with the extent of neuroprotection/restoration observed is 
suggestive that valproate’s inhibition of HDACs is at least partly responsible for the effects 
observed.  
Addition of an acetyl group to histone lysine residues neutralises the positive charge 
of the residue and hence reduces the electrostatic interaction between the lysine in the histone 
tail and the negatively charged phosphate group on DNA. This disrupts the inter- and intra-
nucleosomal interactions between the histone and DNA and hence relaxes the structure of the 
chromatin allowing transcription factor access. Inhibition of HDACs and histone acetylation 
in the brain have therefore been shown to be associated with transcriptional upregulation of 
numerous factors that are thought to contribute to the neuroprotective/restorative effects 
observed by valproate (Monti et al., 2009). Similarly we have observed that the neurotrophic 
factors BDNF and GDNF are significantly upregulated upon valproate treatment, confirming 
the studies by Wu and colleagues (Wu et al., 2008) who demonstrated that an astrocytic cell 
line treated with valproate displays a time dependent increase in expression of both BDNF 
and GDNF; an effect which translated to neuroprotection in midbrain neuronal cultures in 
medium transfer experiments. Additionally, Wu and colleagues demonstrated that the GDNF 
promoter associated histone H3 is significantly hyperacetylated when astrocytes are treated 
with valproate. Importantly, we also showed in this animal study for the first time that gene 
expression of the anti-apoptotic molecule BCL2 is upregulated upon valproate treatment, and 
the pro-apoptotic molecule BAD is downregulated. This is in agreement with previously data 
from Kidd and Schneider (2010) in which dopaminergic cells treated with valproate in vitro 
displayed a reduction in MPP+ induced activation of caspase-3 indicative of apoptosis 
inhibition. The findings from the current study therefore suggest that valproate’s mechanism 
of histone acetylation mediated neuroprotection/restoration is a multifaceted and complex 
affair, one which may hold therapeutic potential against a complex disorder such as PD.  
The doses of valproate administered to rats in this study translate to human equivalent 
doses of 64 and 32mg/kg/day (400 and 200mg/kg/day rat dose respectively, since rats 
metabolise valproate quicker) (as calculated using FDA guidelines (FDA, 2005)). These 
doses are far greater than the usual therapeutic maintenance dose of valproate used for the 
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treatment of epilepsy in humans (1000-2000mg/day) and hence may result in increased 
incidence of side effects such as extrapyramidal effects, tremor, sleepiness, cognitive 
problems etc. if administered to humans (Britain, 2009). Obviously, such side effects would 
aggravate PD symptomology, hence valproate itself, at the doses examined here, may not be 
a candidate for repositioning for PD. However, the current study acts as proof-of-principle 
that delayed start treatment with a HDACI is capable of producing a neuroprotective 
phenotype in this animal model of PD. 
In conclusion, utilising a clinically relevant drug testing platform this study clearly 
demonstrates that the HDACI valproate is dose-dependently neuroprotective and 
neurorestorative in the lactacystin rodent model of PD when administered chronically starting 
seven days after the toxin administration when behavioural and MRI deficits are already 
evident and a significant deficit in dopaminergic neurons is observed. These effects of 
valproate are associated with a reversal of histone hypoacetylation and an upregulation of 
neuroprotective and neurotrophic factors. This therefore supports the potential 
neuroprotective benefits of HDAC inhibition in PD and advocates further investigation of 
which specific HDAC isoforms are responsible for the neuroprotective effects of valproate in 
lieu of a clinically translatable HDACI treatment strategy for PD. 
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Figure Legends 
Figure 1 - Animal Treatment Groups and Study Design 
*All daily i.p. injections given as 2ml/kg: saline injections given as 2ml/kg empty saline; 
400mg/kg valproate injections given as 2ml/kg of 200mg/ml solution of valproate in saline; 
200mg/kg valproate injections given as 2ml/kg of 100mg/ml solution of valproate in saline. 
#Only groups Lacta(+)VPA(-), Lacta(+)VPA(+) and Lacta(+)VPA(++) intranigrally injected 
with lactacystin. Control groups remained surgically naïve. 
ǂOnly groups lesioned with lactacystin were tested using the amphetamine induced rotation 
test at these time points.   
Abbreviations: VCT, vertical cylinder test; AIR, amphetamine induced rotations; MRI, 
magnetic resonance imaging.  
 
Figure 2 - Valproate Attenuates Behavioural Motor Deficits Caused by Lactacystin  
(A) Vertical cylinder test outcomes show that once animals begin treatment with valproate at 
week 1 the lactacystin induced reduction in percentage contralateral forelimb use is reversed 
in a dose-dependent manner. (B and C) Amphetamine induced rotation test outcomes show 
that animals treated with valproate perform dose-dependently less rotations at each of the 
examined time points after starting treatment with valproate at week 1. Statistical significance 
denoted with either asterisks: (*p<0.05) or letters if p<0.05 for each comparison (see text for 
degrees of significance) : a, significantly different from group Lacta(-)VPA(-); b, significantly 
different from group Lacta(-)VPA(++); c, significantly different from group Lacta(+)VPA(-); 
d, significantly different from group Lacta(+)VPA(+). Data is presented as mean ± SEM. n = 
6-7 per group. Abbreviations: Lacta(-), lactacystin-naïve; Lacta(+), lactacystin-lesioned; 
VPA(-), treated with vehicle; VPA(+), treated with 200mg/kg/day valproate; VPA(++), 
treated with 400mg/kg/day valproate.   
 
Figure 3 - Manual Segmentation Analysis of MR Images Reveals Dose-dependent 
Attenuation of Lactacystin Induced Volumetric Changes by Valproate 
Administration of valproate dose-dependently attenuates volumetric changes observed in the 
(B) lateral ventricles and (C) the midbrain as a result of lactacystin-lesioning, as ascertained 
through manual segmentation analysis of rat brain MR images. Similarly administration of 
valproate and/or lactacystin have marked effects on (A) whole brain volume. Statistical 
significance denoted with letters if p<0.05 for each comparison (see text for degrees of 
significance): a, significantly different from group Lacta(-)VPA(-); b, significantly different 
from group Lacta(-)VPA(++); c, significantly different from group Lacta(+)VPA(-); d, 
significantly different from group Lacta(+)VPA(+). Data is presented as mean ± SEM. n = 6-
7 per group. Abbreviations: Lacta(-), lactacystin-naïve; Lacta(+), lactacystin-lesioned; VPA(-
), treated with vehicle; VPA(+), treated with 200mg/kg/day valproate; VPA(++), treated with 
400mg/kg/day valproate. See also Supplementary Fig. 2. 
 
Figure 4 - Tensor Based Morphometry Validates Findings From Manual Segmentation 
Analyses of Rat Brain MR Images 
Regions of significant volume difference relative to whole brain for each group compared 
with Lacta(-)VPA(-) at week 5 are shown. Positive differences indicate where each group has 
volume increases compared with Lacta(-)VPA(-) and negative differences indicate where 
each group has volume decreases compared with Lacta(-)VPA(-). Results shown are 
significant after correction for multiple comparisons across voxels using the False Discovery 
Rate with q=0.05. n = 6-7 per group. Abbreviations: Lacta(-), lactacystin-naïve; Lacta(+), 
lactacystin-lesioned; VPA(-), treated with vehicle; VPA(+), treated with 200mg/kg/day 
valproate; VPA(++), treated with 400mg/kg/day valproate.   
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Figure 5 - Valproate Treatment Causes Dose-dependent Protection/Restoration of 
Dopaminergic Neurons in the SNpc in Lactacystin Lesioned Animals 
Stereologically estimated (A) TH+ and (B) Nissl+ neuron numbers in the SNpc of rats 
suggest a dose-dependent neuroprotective/restorative effect of valproate in this lactacystin rat 
model of Parkinson’s disease. This is exemplified by the percentage interhemispheric loss of 
TH+ (C) and Nissl+ (D) neurons calculated between hemispheres of the SNpc. Statistical 
significance indicated with asterisks: *p<0.05; **p<0.01, ***p<0.001. Data is presented as 
mean ± SEM. n = 6-7 per group. Abbreviations: C, contralateral; I, ipsilateral; Lacta(-), 
lactacystin-naïve; Lacta(+), lactacystin-lesioned; VPA(-), treated with vehicle; VPA(+), 
treated with 200mg/kg/day valproate; VPA(++), treated with 400mg/kg/day valproate. 
 
Figure 6 – Neuroprotection/Restoration in the SNpc of Lactacystin Lesioned Animals 
Representative examples of the TH and Nissl stained ipsilateral (A-F) and contralateral (A’-
F’) SNpc of rats in each of the five treatment groups and group of animals sacrificed prior to 
drug treatment. Scale bar equal to 500µm. Abbreviations: Lacta(-), lactacystin-naïve; 
Lacta(+), lactacystin-lesioned; VPA(-), treated with vehicle; VPA(+), treated with 
200mg/kg/day valproate; VPA(++), treated with 400mg/kg/day valproate.   
 
Figure 7 - Valproate Attenuates Lactacystin Induced Reduction in Frontal Brain 
Histone Acetylation  
Administration of systemic valproate dose-dependently reverses the reduction in histone H3-
lysine 9 acetylation caused by lactacystin. (A) Densitometry analysis of the AcH3-Lys9 band 
relative to the β-actin band used as a loading control. (B) Representative blot of data 
presented in (A). Statistical significance indicated with asterisks: *p<0.05; **p<0.01. Data is 
presented as mean ± SEM. n = 6-7 per group. Abbreviations: C, contralateral; I, ipsilateral; 
Lacta(-), lactacystin-naïve; Lacta(+), lactacystin-lesioned; VPA(-), treated with vehicle; 
VPA(+), treated with 200mg/kg/day valproate; VPA(++), treated with 400mg/kg/day 
valproate.   
 
Figure 8 - Valproate Upregulates Expression of Neuroprotective and Neurotrophic 
Growth Factor mRNA in the Frontal Brain 
(A) Administration of systemic valproate alone, in surgically naïve rats upregulates bilateral 
expression of BDNF. (B) In lactacystin-lesioned animals valproate dose-dependently up 
regulated unilateral expression of αSyn, BDNF, GDNF, HSP70 and BCL2, as well as 
reducing the expression of BAD when given at its highest dose. Statistical significance 
indicated with asterisks and hashes: *p<0.05, **p<0.01, ***p<0.001 compared with the same 
hemisphere of saline treated group; #p<0.05, ##p<0.01, ###p<0.001 compared with the same 
hemisphere of Lacta(+)VPA(+). Data is presented as mean ± SEM. n = 6-7 per group. 
Abbreviations: C, contralateral; I, ipsilateral; Lacta(-), lactacystin-naïve; Lacta(+), 
lactacystin-lesioned; VPA(-), treated with vehicle; VPA(+), treated with 200mg/kg/day 
valproate; VPA(++), treated with 400mg/kg/day valproate.  See also Supplementary Table 1. 
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